IRBESARTAN IN THE CLINICAL PRACTICE
<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | http://www.rpcardio.ru/jour/article/view/306 |
| _version_ | 1827836853735129088 |
|---|---|
| author | V. I. Podzolkov A. I. Tarzimanova |
| author_facet | V. I. Podzolkov A. I. Tarzimanova |
| author_sort | V. I. Podzolkov |
| collection | DOAJ |
| description | <p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.</p> |
| first_indexed | 2024-03-12T06:34:12Z |
| format | Article |
| id | doaj.art-76222f482f73492a97cded9e8ddcdeb8 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-03-12T06:34:12Z |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-76222f482f73492a97cded9e8ddcdeb82023-09-03T01:25:37ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0110665966410.1234/1819-6446-2014-6-659-664306IRBESARTAN IN THE CLINICAL PRACTICEV. I. Podzolkov0A. I. Tarzimanova1Первый Московский Государственный Медицинский Университет им. И.М. СеченоваПервый Московский Государственный Медицинский Университет им. И.М. Сеченова<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.</p>http://www.rpcardio.ru/jour/article/view/306ирбесартанблокаторы рецепторов к ангиотензинуартериальная гипертензиянефропротективный эффект |
| spellingShingle | V. I. Podzolkov A. I. Tarzimanova IRBESARTAN IN THE CLINICAL PRACTICE Рациональная фармакотерапия в кардиологии ирбесартан блокаторы рецепторов к ангиотензину артериальная гипертензия нефропротективный эффект |
| title | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_full | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_fullStr | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_full_unstemmed | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_short | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_sort | irbesartan in the clinical practice |
| topic | ирбесартан блокаторы рецепторов к ангиотензину артериальная гипертензия нефропротективный эффект |
| url | http://www.rpcardio.ru/jour/article/view/306 |
| work_keys_str_mv | AT vipodzolkov irbesartanintheclinicalpractice AT aitarzimanova irbesartanintheclinicalpractice |